FDA Clearance Tracker · P150034
Raindrop Near Vision Inlay
Last checked: Nov 19, 2026Latest source record: Jun 29, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Jun 29, 2016
Approved
Time to decision
279 days
Received Sep 24, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150034
- Device name
- Raindrop Near Vision Inlay
- Applicant location
- Aliso Viejo, CA
- Received
- Sep 24, 2015
- Decided
- Jun 29, 2016
- Decision
- Approved
- Supplements
- 9 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Implant, corneal, refractive (LQE)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the Raindrop® Near Vision Inlay. This device is indicated for intrastromal implantation to improve near vision in the non-dominant eye of phakic, presbyopic patients, 41 to 65 years of age, who have manifest refractive spherical equivalent of (MRSE) +1.00 diopters (D) to -0.50 D with less than or equal to 0.75 D of refractive cylinder, who do not require correction for clear distance vision, but who do require near correction of +1.50 D to +2.50 D of reading add.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LQE. The earliest in FDA's data is P980031, decided Apr 9, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Rvo 2.0, Inc. (D.B.A. Optics Medical)
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.